Kornimate/medical-research-clean huggingface dataset:
study of folfox4 chemotherapy regimen to prevent early postoperative recurrence for hcc-pvtt patients

Conditions: Carcinoma, Hepatocellular

Summary: this study is to investigate the efficacy and safety of folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection

curative resective is well-accepted as the predominant treatment for hepatocellular carcinoma (hcc) patients. unfortunately, the long-term prognosis remains poor due to frequent postoperative recurrence, especially in hcc patients with portal vein tumor thrombus (pvtt). when pvtt invades into the portal vein system, tumor cell spreads and distributes along with the portal vein and its branches,thus resulting in intra-hepatic micro-metastasis which contributes to early recurrence for patients following curative resection. postoperative adjuvant interventions include tace, antiviral therapy, immunotherapy, local radiotherapy were applied to prevent recurrence. however, the efficacy and safety of these regimens remains unsatisfactory. thus new therapeutic strategy remains to be investigated. this study is to investigate the efficacy and safety of folfox4 chemotherapy regimen to prevent early recurrence for hcc patients with pvtt following curative resection.

Eligibility criteria:
inclusion criteria: * patients undergo curative resection * hcc with pvtt is confirmed by pathological examination * patients undergo chemotherapy of folfox4 regimen * patients without recurrence within the first month after curative resection * residual hepatic function is child-pugh a or b which is capable to tolerate chemotherapy * patients without other postoperative adjuvant treatments including tace, radiotherapy, immunotherapy exclusion criteria: * multipal intra-hepatic or outra-hepatic tastasis within the first month after curative resection * patients with residual hepatic function child-pugh c is not capable to tolerate chemotherapy * patients undergo postoperative adjuvant treatments except chemotherapy of folfox4 regimen * patients with badly chemotherapy complications who can finish the whole folfox4 treatment course

Keywords: hcc pvtt folofox4 early recurrence
improving drug dosing and outcomes for single ventricle patients with fontan associated liver disease

Conditions: Fontan Circulation

Summary: this is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with fontan circulation.


Eligibility criteria:
inclusion criteria: * \> 8 years * status post fontan completion * ability to provide informed permission-assent (\<18 years) or consent (≥18 years) * fasting overnight (\~8 hours) exclusion criteria: * pregnancy * non-fasting * non-removable metal in body or where magnetic resonance imaging (mri) is considered unsafe * sildenafil and/or pravastatin therapy within last 2 months * history of underlying or laboratory evidence of underlying intestinal, metabolic, autoimmune, renal disease that can alter sildenafil and pravastatin disposition (absorption, metabolism, distribution, or clearance) * pharmacotherapy that interacts with sildenafil (cytochrome p450 3a4 and p450 3a5 (cyp3a4/5) inducers/inhibitors) and/or pravastatin (organic anion transporting polypeptide (oatp1b1) inducers/inhibitors) * inability to swallow a tablet * \>5x the age-specific upper limit of normal for aspartate aminotransferase (ast) and alanine aminotransferase (alt), total and conjugated bilirubin * diarrhea in the last 24 hours \*history of solid organ transplantation

Keywords: fontan fald
efficacy and safety of nitazoxanide 600 mg in the outpatient treatment of covid-19 and influenza

Conditions: Covid 19; Influenza

Summary: 2. participants will: * take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. * visit the clinic on the 7th day of treatment for a check-up and safety tests. * keep a diary of their symptoms and other medications used


Eligibility criteria:
inclusion criteria: * signed informed consent form; * male or female; * age ≥ 18 years; * covid-19 or influenza diagnosed by rapid test, with symptom onset less than 48 hours ago; * clinical condition compatible with outpatient treatment. exclusion criteria: * known hypersensitivity to nitazoxanide; * history of cardiomyopathies, hepatopathies, or nephropathies; * antineoplastic treatment with chemotherapy or radiotherapy; * severe autoimmune diseases with immunosuppression; * transplant recipients; * any uncompensated systemic disease at the investigator's discretion; * participation in clinical studies in the last 12 months; * pregnant or breastfeeding individuals; * suspected bacterial coinfection or prescription of antibiotic therapy at enrollment; * diagnosis of neurological disease (traumatic brain injury, stroke, parkinson's disease, alzheimer's disease, other dementias); * diagnosis of developmental disorder (adhd, asd, learning disabilities, intellectual disability, rett syndrome); * significant hearing or vision impairment.

Keywords: nitazoxanide outpatient treatment
effects of exercise in combination with epoetin alfa

Conditions: Multiple Myeloma

Summary: the purpose of the study was to determine the effect of epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training for patients being treated with high-dose chemotherapy and autologous peripheral bloodstem cell transplantation (pbsc t) for multiple myeloma. the endpoints for the study included the number of attempts at and total number of days of stem cell collection, number of rbc and platelet transfusions during the transplantation period, time-to-recovery after transplantation, and response to intensive therapy for multiple myeloma.


Eligibility criteria:
inclusion criteria: * those who were not at high risk for impending pathologic fracture or cord compression, as determined by magnetic resonance imaging and other radiology reports and physician assessments,and enrolled in total therapy treatment protocols were invited to participate in the study. exclusion criteria: patients were excluded if they showed any of the following attributes/conditions: * inability to understand the intent of the study * current diagnosis with a major psychiatric illness * presence of microcytic or macrocytic anemia * uncontrolled hypertension * red cell transfusions within 2 weeks; and * recombinant epoetin alfa within 8 weeks of study enrollment.

Keywords: multiple myeloma polysomnography quality of life exercise
inflammation in peritoneal dialysis patients: effect of obesity

Conditions: End-Stage Renal Disease; Renal Disease, End-Stage; Renal Failure, End-Stage; Obesity

Summary: our study addresses the following research question: what is the role of obesity in modulating inflammation and innate immune function, as well as the overall responsiveness of innate immune cells (such as macrophages, neutrophils, and other peripheral leukocytes) in patients undergoing peritoneal dialysis? the investigators hypothesize that obesity will lead to increased inflammation in patients undergoing peritoneal dialysis.

chronic inflammation is highly prevalent in esrd and associated with adverse outcomes. for example, chronic exposure of the peritoneal cavity to pd solution leads to induction of cytokines and other inflammatory mediators, generating peritoneal membrane inflammation which results in functional decline of ultrafiltration. obesity is characterized by a state of chronic low-grade systemic inflammation stemming from expanded adipose tissue mass. animal studies from our group and others suggest that obesity is associated with exacerbated prolonged inflammatory responses in the peritoneal cavity. the shifting demographic characteristics of the esrd population, with a rise in elderly patients and those with obesity, is as a significant challenge for management of dialysis patients. specifically, a 2-fold increase in the percentage of obese patients in the esrd population has been reported. the caloric burden of pd glucose-containing solutions adds an additional risk for development or exacerbation of obesity and diabetes in patients using this dialysis modality. few studies have directly evaluated the association between degree of adiposity and inflammation in pd patients. data obtained from the proposed experiments will help clarify the connection between obesity and risk factors for cardiovascular and infectious diseases in the pd population. these data will also further our knowledge of the basic pathophysiology of both obesity and esrd and enhance our understanding of factors involved in successful delivery of pd. results may lead to enhanced nutritional recommendations for pd patients and/or the use of low-glucose or non-glucose alternatives, with a resultant reduction in local and/or systemic inflammation and cvd and other risk factors.

Eligibility criteria:
inclusion criteria: 1. \> 18 years; and 2. peritoneal dialysis (pd) \> 6 months. exclusion criteria: 1. infectious episode within 4 weeks; and 2. using immunosuppressive drugs

Keywords: obesity peritoneal dialysis inflammation macrophages innate immunity
shocking therapy for chronic pelvic pain syndrome

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Summary: chronic prostatitis/chronic pelvic pain syndrome is an extremely common urologic diagnosis and accounts for approximately 2 million outpatient visits to urology practices in the united states alone. up to 6% of men in canada recently experienced at least moderate to severe prostatitis-like symptoms with two thirds having symptoms lasting more than one year. there are a myriad of therapies for prostatitis, some of which work on some of the men but none works for all the men. recently, a number of centres have been using low energy shock waves applied on the skin to target the prostate and the muscles around the prostate. the initial reports showed a significant reduction in the pain experienced by the men with prostatitis. however, this potentially highly promising therapy has not been widely used at least in part due to a lack of properly designed studies to validate this therapy. the investigators plan a randomized control trial using shock wave therapy on men with prostatitis. the goal is to provide some solid evidence that either shock waves are or are not of clinical benefit. the investigators hypothesize men with chronic prostatitis/ chronic pelvic pain syndrome will have a reduction in pain and improved voiding and sexual function following low power transdermal shock wave therapy to the prostate and surrounding pelvic muscles.


Eligibility criteria:
inclusion criteria: * exhibit symptoms of pain typical for prostatitis/cpps * have had the symptoms for at least 3 months * have no evidence of infection in the urine or expressed prostatic secretions (the seminal plasma may be substituted if expressed prostatic secretions are not available). * have failed at least one therapy for cpps exclusion criteria: * suspected or confirmed to have prostate cancer * have a coagulation disorders * use anticoagulants * have thrombosis * have used cortisone therapy up to 6 weeks before first treatment * are actively trying to conceive

Keywords: chronic pelvic pain syndrome chronic prostatitis shock wave therapy prostate pelvic floor pain
application of mixed reality technique for percutaneous lung nodule localization: a prospective, randomized, controlled trial

Conditions: Lung Cancer

Summary: with the popularization of ct screening, the detection rate of small lung nodules has greatly increased. therefore, the clinical thoracoscopic lung nodule biopsy and sub-lobectomy for radical resection of lung cancer are greatly required. accurate resection of lung nodule depends on precise localization of pulmonary nodules. however, preoperative ct-guided hook- wire positioning under local anesthesia, which is the current primary localization method, requires high equipment and expense, and may cause physical and mental trauma to the patient. augmented reality (ar) is an innovative technology that superimpose a virtual scene into the real environment by fusing images, videos, or computer-generated models with patients during surgical operations. it can visually display the anatomical structures of organs or lesions, which significantly improves surgical efficiency. this project intends to use ar technology to localize the solitary pulmonary nodule (spn) before surgery, compared with ct-guided hook-wire localization. compared with the localization of spns under ct guidance, ar-assisted localization technology apparently is less time-consuming and can be performed immediately before surgery under general anesthesia, lessening pain, reduce costs of time and equipment, increase the success rate of sub-lobectomy, and improve the overall efficiency of surgical treatment of pulmonary nodules.


Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18years of age; 2. there was no distant metastasis in preoperative clinical evaluation; 3. the attending physician evaluated and confirmed the need for lung nodule localization and sub-lobectomy; 4. target lung nodule diameter ≤ 2cm 5. the inner edge of the target node is at least 2 cm from the pulmonary artery or pulmonary vein 6. preoperative ecog physical state score 0/1; 7. volunteer to participate in the study and sign the informed consent form. exclusion criteria: 1. more than two lung nodules need to be removed at the same time. 2. the target node is located in the scapular region. because percutaneous localization is obstructed by the scapula, percutaneous localization of pulmonary nodules is not suitable for such patients. 3. the patient has uncontrollable mental illness and cannot make subjective assessment. 4. after being selected, severe complications (unable to tolerate surgery or anesthesia) occurred before operation are not suitable or the treatment plan of the study cannot be implemented as planned; 5. after being selected, the patient's condition changes and needs to be changed from elective surgery to emergency surgery after being confirmed by the competent doctor; 6. at any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.

Keywords: mixed reality localization sublobectomy
fenofibrate in combination with ursodeoxycholic acid (udca) in primary biliary cirrhosis

Conditions: Primary Biliary Cirrhosis

Summary: the purpose of this study is to determine if the combination of ursodeoxycholic acid (udca) and fenofibrate is more effective than udca alone in the treatment of primary biliary cirrhosis.


Eligibility criteria:
inclusion criteria: 1. age ≥ 21 and ≤ 75 years old 2. established diagnosis of pbc and positive ama 3. previous treatment with udca 13-15 mg/kg/day for at least 1 year 4. incomplete response to udca defined as serum alp ≥ 2 times the upper limit of normal on two separate measurements despite at least 1 year of therapy with udca 5. female patients of childbearing age need a negative pregnancy test performed within 7 days of enrollment, and need to be on adequate contraception throughout the study period 6. signed informed consent after careful review of information and study details exclusion criteria: 1. hypersensitivity to fenofibrate 2. administration of the following drugs at any time during the 3 months prior to screening for the study: methotrexate, colchicines, azathioprine, systemic steroids. 3. prisoners and institutionalized subjects, pregnant or nursing women 4. anticipated need for liver transplantation within one year (estimated 1-year survival \<80% as predicted by the mayo risk score). 5. recipients of liver transplantation 6. recurrent variceal hemorrhage, uncontrolled encephalopathy or refractory ascites 7. co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fatty liver disease, wilson's disease and hemochromatosis 8. acute or chronic renal failure, defined as gfr \< 60 ml/min 9. known history of cholecystitis with intact gallbladder 10. history of, or known high risk for, venous thromboembolism 11. current use of warfarin or statins
use of fiber-optic probe for non-invasive diagnosis of melanoma and assessment of impact of ultraviolet (uv) exposure on skin

Conditions: Melanoma

Summary: this study is designed to collect information about melanoma using a research probe, a device placed only on the skin. this study will investigate whether using the probe to examine skin lesions could improve the accuracy of identification pre-cancerous melanoma lesions or to predict the risk melanoma in the skin of subjects. ultimately, we would see this technique used routinely as a non-invasive device during subjects' skin examination to aid dermatologists to identify pre-cancerous (melanoma) lesions without taking tissue samples of the skin. alternatively, this technique would, in the future, also be used to screen patients at risk for melanoma.


Eligibility criteria:
inclusion criteria: * male and female above 18 years of age; * subjects who are planned to undergo skin examinations with and without atypical nevi, with and without personal or family history of melanoma and potentially with pigmented lesions to be removed for medical care or cosmetic purposes. exclusion criteria: * individuals whose pathology cannot be obtained or retrieved. * inability to provide informed consent.

Keywords: fiber optic melanoma uv exposure
safety and efficacy clinical study of sns-595 in patients with advanced small cell lung cancer

Conditions: Carcinoma, Small Cell; Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the objective tumor response rate to sns-595 in patients with small cell lung cancer (sclc).

other objectives of this study are to assess the safety, survival rate, best response, time to disease progression, duration of tumor response, and to explore several potential biomarkers to see how these levels change after administration of sns-595.

Eligibility criteria:
inclusion criteria: * able to understand and willing to sign a written informed consent document * patients who have recurrent or refractory sclc requiring second-line chemotherapy who previously received first-line chemotherapy * measurable disease * eastern cooperative oncology group (ecog) performance status score of 0, 1, or 2 * brain metastasis may be included if the patient is neurologically stable and has been off steroids and anticonvulsants for at least 4 weeks prior to cycle 1 day 0 * laboratory values within the normal or reasonable reference range as specified by the protocol exclusion criteria: * prior exposure to sns-595 * pregnant or breastfeeding * women of childbearing potential, or male partners of women of childbearing potential, unwilling to use an approved, effective means of contraception according to the institution's standards * other active malignancies or other malignancies within the past 12 months, other than non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostatic intraepithelial neoplasia * q-wave myocardial infarction or cerebrovascular accident/transient ischemic attack (tia) within 6 months before the first sns-595 dose * thromboembolic event (deep vein thrombosis or pulmonary embolus) within 28 days before the first sns-595 dose * requires kidney dialysis (hemodialysis or peritoneal) * prior chemotherapy, investigational agents, or radiation therapy within 28 days before cycle 1 day 0; however, nitrosoureas, mitomycin c, and therapeutic monoclonal antibodies are not permitted for at least 42 days before cycle 1 day 0 * in patients with toxicities caused by prior cancer therapy, those toxicities must have returned to less than or equal to grade 1, with the exception of alopecia. * prior pelvic radiation therapy or radiation to greater than 25% of bone marrow reserve; radiation to the brain is permitted up to 28 days before the first sns-595 dose, as long as the patient does not require treatment with corticosteroids for symptom control related to brain metastases. * any other medical, psychological, or social condition that, in the opinion of the principal investigator, would contraindicate the patient's participation in the clinical trial due to safety or compliance with study procedures

Keywords: lung squamous cell small cell carcinoma cancer small cell lung cancer
the effects of kinesio taping on biomechanical and clinical outcomes in runners with iliotibial band friction syndrome

Conditions: Iliotibial Band Syndrome

Summary: the aim of this study is to investigate the efficacy and effectiveness of the application of kinesio taping in the short-term management of itbfs in an exploratory randomized control study in two patient groups, an experimental group receiving kinesio taping with tension, and a control group receiving kinesio taping with no tension.

to determine the immediate effects of taping on the three-dimensional joint kinematics and moments of the lower limb during running in itbfs patients, and to determine any differences between the experimental and control groups. to determine the immediate effects of taping on muscle activity of the gluteus maximus, gluteus medius, tensor fascia lata, vastus medialis, and vastus lateralis in itbfs patients, and to determine any differences between the experimental and control groups. to determine if the short-term perceptions of pain, symptoms, adl function, sport and recreation function, quality of life, and fear of movement are changed with taping, and to determine any differences between the experimental and control groups. to determine any perceived changes in the stability of the knee joint, comfort and benefits with taping, and to determine any differences between the experimental and control groups. to determine if muscle strength, muscle length, and functional movement are changed with taping, and to determine any differences between the experimental and control groups. to explore the relationship between the clinical and biomechanical outcome measures in itbfs patients.

Eligibility criteria:
inclusion criteria: * aged between 18 to 45 years * regularly run a minimum of 10 kilometres a week, * current symptoms of itbfs, assessed using the noble compression test and ober's test, and pain at lateral femoral condyle during running exclusion criteria: * history of taking any analgesic or anti-inflammatory drugs for 72 hours prior to testing. * previous surgery to the lower limbs, * skin allergy to kinesio tape, * signs or symptoms of other knee pathologies including; patellofemoral pain, knee joint osteoarthritis, lateral meniscus injury, common peroneal nerve injury, refer pain from lumbar spine, superior tibiofibular joint sprain, and popliteus or bicep femoris tendinitis.

Keywords: kinesio taping biomechanics iliotibial band friction syndrome clinical outcomes